GPP
ABVX

Great Point Partners’s Abivax ABVX Stock Holding History

Great Point Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.3M Buy
+400,000
New +$45.3M 10.07% 1

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Great Point Partners's ABVX Position: Q2 2026 in Review

Great Point Partners opened a new position in Abivax (ABVX) in Q2 2026: 204,314 shares worth $27.2M. The stake represents 5.15% of the portfolio and ranks #3 among its holdings. This is a return to the name: Great Point Partners previously reported a position in ABVX as recently as Q3 2025.

Great Point Partners first reported a position in ABVX in Q4 2023 and has held it in 9 quarters since. The position peaked at $35.6M in Q1 2024. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Great Point Partners held 204,314 shares of Abivax worth $27.2M as of Q2 2026.
  • Abivax was a new Great Point Partners position in Q2 2026.
  • Abivax made up 5.15% of Great Point Partners's portfolio in Q2 2026, its #3 holding.
  • Great Point Partners first reported a position in Abivax in Q4 2023 and has held it in 9 quarters since.
  • Great Point Partners's Abivax position peaked at $35.6M in Q1 2024.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.